carnosinase
Small moleculeexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04418141)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Angiotensin-converting enzymeINHIBITOR
ACE inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04880564 | Phase 1/Phase 2 (Phase 2) | Jul 28, 2021 | Curon Biopharmaceutical (Australia) Co Pty Ltd, Monash University, Novotech |
| NCT04418141 | Phase 1 | Jun 30, 2020 | Cabrini Hospital (Melbourne), Curon Biopharmaceutical (Australia) Co Pty Ltd, Icon Cancer Centre (Brisbane), Illawarra Cancer Care Centre (Wollongong), Macquarie University Hospital, Novotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Curon Biopharmaceutical (Australia) Co Pty Ltd | For profit | 2 | 2 | 2 | 2020 |
| Novotech | For profit | 2 | 0 | 2 | 2020 |
| Cabrini Hospital (Melbourne) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Icon Cancer Centre (Brisbane) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Illawarra Cancer Care Centre (Wollongong) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Macquarie University Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1